「so」の検索結果
138件：71～75件目を表示
-
IDU「センジュ」
認めるときは、上記 【製品情報お問い合わせ先】 に連絡するとと もに、農林水産省動物医薬品検査所 （https : //www. maff. go. jp/nval/iyakutou/fukusayo/sousa/index. html） にも報告をお願いします。 313‒008 O O I O H H N H OH HN HO 観察項目 眼瞼結膜充血 74.1 ［40/54］ 眼科的症状改善率 （...
https://www.senju.co.jp/system/files/2025-08/idu_202508_313-008_0.pdf -
MytearV | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 2 OTC medicines Mytear® V Resolves redness of the eye and provides healthy and clear eyes. CHARACTERISTICS Compounded with "tetrahydrozoline hydrochloride", a component to relieve r...
https://www.senju.co.jp/english/products/mytearv.html -
研究開発の取り組み | 千寿製薬株式会社
R & D activities Product Development Policy Research and Development System R & D Pipeline Clinical trial information Publications Meetings of the Minds Business Collaboration Inquiries licens
https://www.senju.co.jp/english/rd/ -
Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica
ed States Completed NCT04139122 Disclaimer This website provides information on clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including...
https://www.senju.co.jp/english/rd/trial.html -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
– Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Kazunori Omatsu, BSc the 59th Congress of the European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日 開催地：Athens, GREECE Summary of nonclinical toxicity...
https://www.senju.co.jp/english/rd/society/